Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Advanced Solid Tumors × Nivolumab × Clear all

Phase

Status

Completed 4 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 33 Carcinoma, Non-Small-Cell Lung 29 Carcinoma, Renal Cell 21 Neoplasm Metastasis 16 Lung Neoplasms 16 Carcinoma, Hepatocellular 14 Colorectal Neoplasms 10 Pancreatic Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 8 Carcinoma, Transitional Cell 8 Urinary Bladder Neoplasms 7 Neoplasms 7 Multiple Myeloma 7 Breast Neoplasms 7 Small Cell Lung Carcinoma 6 Hodgkin Disease 6 Head and Neck Neoplasms 6 Triple Negative Breast Neoplasms 5 Ovarian Neoplasms 5 Skin Neoplasms 4 Myelodysplastic Syndromes 4 Lymphoma 4 Kidney Neoplasms 4 Hematologic Neoplasms 4 Glioblastoma 4 Advanced Cancer 4 Prostatic Neoplasms 3 Lymphoma, Non-Hodgkin 3 Liver Neoplasms 3 Fallopian Tube Neoplasms 3

Interventions

Carboplatin 3 Docetaxel 2 Cisplatin 2 BMS-753493 2 zimberelimab 1 tislelizumab 1 tesetaxel 1 spartalizumab 1 pembrolizumab 1 olaparib 1 liposomal doxorubicin 1 linifanib 1 lenvatinib 1 ixabepilone 1 durvalumab 1 avelumab 1 avdoralimab 1 adavosertib 1 TAS-119 1 Rifampin 1 Nivolumab 1 N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1 Maximum Tolerated Dose 1 Linoleic Acids, Conjugated 1 Lapatinib 1 Itraconazole 1 Irinotecan 1 Ipilimumab 1 Injections 1 Ifosfamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03461952 2024-02-22

NIMBLe

Canadian Cancer Trials Group

Phase 2 Terminated

4 enrolled 4 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡